Novo Nordisk

With B shares listed in both London and Copenhagen, Novo Nordisk fulfils a niche market requirement in the development and exploration of mainly diabetes products and care, although the company does venture into different sectors. Winning many awards for its green and ethical platform, it has also been recognised for its market design and branding capabilities. Recently, the company has struck up a campaign to provide global awareness of the effects and symptoms of diabetes. It has also opened new research centres with the hope of finding cures for the disease, and biotech centres across Seattle to assist treatment.